[go: up one dir, main page]

WO2012083356A1 - Dispositif à écoulement latéral pour la détection de diuron - Google Patents

Dispositif à écoulement latéral pour la détection de diuron Download PDF

Info

Publication number
WO2012083356A1
WO2012083356A1 PCT/AU2011/001645 AU2011001645W WO2012083356A1 WO 2012083356 A1 WO2012083356 A1 WO 2012083356A1 AU 2011001645 W AU2011001645 W AU 2011001645W WO 2012083356 A1 WO2012083356 A1 WO 2012083356A1
Authority
WO
WIPO (PCT)
Prior art keywords
diuron
antibody
hapten
reaction site
liquid sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2011/001645
Other languages
English (en)
Inventor
Ivan Robert KENNEDY
Angus Neill CROSSAN
Wang SHUO
Zhang YAN
Wei SHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cotton Catchment Communities Coopertive Research Centre Ltd
Original Assignee
Cotton Catchment Communities Coopertive Research Centre Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201010609718.2A external-priority patent/CN102539732B/zh
Priority claimed from AU2011900884A external-priority patent/AU2011900884A0/en
Application filed by Cotton Catchment Communities Coopertive Research Centre Ltd filed Critical Cotton Catchment Communities Coopertive Research Centre Ltd
Priority to AU2011349119A priority Critical patent/AU2011349119B2/en
Publication of WO2012083356A1 publication Critical patent/WO2012083356A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow

Definitions

  • the present invention relates to a lateral flow device for the detection of diuron, to methods of
  • Diuron (3- (3, 4-dichlorophenyl ) -1, 1-dimethylurea) is one of a family of arylurea herbicides that was
  • Diuron is used extensively in agriculture in many countries including the United States, Australia, Europe, and China.
  • the herbicide is used as a soil sterilent on non-crop lands, industrial sites, and small amounts are used for selective pre- or post- emergence control of grasses and broad leaf weeds among vegetables, potatoes, cotton, corn, beans, cereals and orchards and vineyards.
  • the standard analytical methods for detection of diuron include spectrophotometry, gas chromatography/mass spectrometry (GC/MS), and high performance liquid
  • the invention provides a lateral flow device for detection of diuron in a sample comprising:
  • a substrate comprising a sample receiving portion and a reaction site, the substrate being structured to permit movement of a liquid sample from the sample receiving portion to the reaction site;
  • an anti-diuron antibody at a second location that is separate from the first location, the hapten and anti-diuron antibody being arranged such that when the liquid sample is applied to the sample receiving portion, the hapten, antibody and liquid sample are combined at the reaction site by movement of the liquid sample from the sample receiving portion to the reaction site.
  • the lateral flow device for detection of diuron in a sample comprises:
  • a substrate comprising a sample receiving portion and a reaction site, the substrate being structured to permit movement of a liquid sample from the sample receiving portion to the reaction site;
  • a hapten of diuron at a first location, wherein the first location is at the reaction site;
  • an anti-diuron antibody at a second location that is separate from the reaction site, the hapten and anti-diuron antibody being arranged such that when the liquid sample is applied to the sample receiving portion, the antibody is transported to the reaction site by movement of the liquid sample from the sample receiving portion to the reaction site.
  • Movement of the liquid sample from the sample receiving portion to the reaction site thereby combines the anti-diuron antibody and liquid sample with the hapten of diuron at the reaction site.
  • the lateral flow device for detection of diuron in a sample comprises: (a) a substrate comprising a sample receiving portion and a reaction site, the substrate being structured to permit movement of a liquid sample from the sample receiving portion to the reaction site; (b) a hapten of diuron at a first location, wherein the first location is at the reaction site;
  • control antibody at a control location that is at the reaction site and separate from the first location, wherein the control antibody is capable of binding the anti-diuron antibody, the hapten, anti-diuron antibody and control antibody being arranged such that when the liquid sample is applied to the sample receiving portion, the anti-diuron antibody is transported to the reaction site by movement of the liquid sample from the sample receiving portion to the reaction site.
  • receiving portion to the reaction site thereby combines the anti-diuron antibody and liquid sample with the hapten of diuron and the control antibody at the reaction site.
  • the invention provides a method of detecting whether diuron is present in a liquid sample, comprising:
  • a substrate comprising a sample receiving portion and a reaction site, the substrate being structured to permit movement of a liquid sample from the sample receiving portion to the reaction site;
  • an anti-diuron antibody at a second location that is separate from the first location, the hapten and antibody being arranged such that when the liquid sample is applied to the sample receiving portion, the hapten, antibody and liquid sample are combined at the reaction site by movement of the liquid sample from the sample receiving portion to the reaction site; - allowing sufficient time for the hapten, anti-diuron antibody and liquid sample to combine at the reaction site; and
  • the method of detecting whether diuron is present in a liquid sample comprises : - applying the liquid sample to a lateral flow device comprising;
  • a substrate comprising a sample receiving portion and a reaction site, the substrate being structured to permit movement of a liquid sample from the sample receiving portion to the reaction site;
  • an anti-diuron antibody at a second location that is separate from the reaction site, the hapten and anti-diuron antibody being arranged such that when the liquid sample is applied to the sample receiving portion, the antibody is transported to the reaction site by movement of the liquid sample from the sample receiving portion to the reaction site
  • the method of detecting whether diuron is present in a liquid sample comprises : - applying the liquid sample to a lateral flow device comprising;
  • a substrate comprising a sample receiving portion and a reaction site, the substrate being structured to permit movement of a liquid sample from the sample receiving portion to the reaction site;
  • control antibody at a control location that is at the reaction site and separate from the first location, wherein the control antibody is capable of binding the anti-diuron antibody, the hapten, anti-diuron antibody and control antibody being arranged such that when the liquid sample is applied to the sample receiving portion, the anti-diuron antibody is transported to the reaction site by movement of the liquid sample from the sample receiving portion to the reaction site
  • the invention provides a kit comprising the lateral flow device of the invention. Brief description of the Figures
  • Fig. 1 is a top view (above) and side view (below) of the arrangement of components of one embodiment of the lateral flow device.
  • Fig. 2 is a perspective view of the arrangement of components of one embodiment of the lateral flow device.
  • Fig. 3 is a schematic representation of the result obtained using the lateral flow device with a diuron- positive sample (A) and diuron-negative sample (B) .
  • Fig. 4A is a graph of the results of a competitive- indirect ELISA with coating antigen hapten 4C-OVA or hapten 6C-OVA.
  • Fig. 4B is a graph of the results of a competitive-direct ELISA showing inhibition of binding of antibody with increasing concentration of coating antibody.
  • Fig. 4C is a graph showing the results of a competitive ELISA with varying pH.
  • Fig. 4D is a graph showing the result of a competitive- direct ELISA using antibody raised against hapten 4C-KLH.
  • the invention relates in one aspect to a lateral flow device for detection of diuron in a sample
  • a substrate comprising a sample receiving portion and a reaction site, the substrate being structured to permit movement of a liquid sample from the sample receiving portion to the reaction site;
  • the hapten and anti-diuron antibody are arranged such that when the liquid sample is applied to the sample receiving portion, the hapten, antibody and liquid sample are combined at the reaction site by movement of the liquid sample from the sample receiving portion to the reaction site.
  • the first location is typically a location on or in the substrate.
  • the second location is typically a location on or in the substrate.
  • the first location is a location on or in the substrate, and the second location is a location on or in the substrate.
  • the second location is separate from the first location.
  • the anti-diuron antibody binds to the hapten at the reaction site when diuron is absent from the liquid sample, and binding of the anti-diuron antibody to the hapten at the reaction site is reduced when diuron is present in the test sample.
  • a lateral flow device is a device for the detection of an analyte in which reagents are combined by moving through a substrate, typically by capillary action.
  • the lateral flow device of the present invention employs a competitive immunoassay to detect the diuron.
  • the device in use the device utilises the ability of the diuron in a sample to bind to the anti-diuron antibody and inhibit binding of the antibody to the hapten to provide an assay for detecting diuron in a sample.
  • the hapten and the anti-diuron antibody are at separate locations in the device, and are combined when a liquid sample applied to the sample receiving portion moves from the sample receiving portion to the reaction site. In this regard, movement of the liquid sample from the sample receiving portion to the reaction site
  • the reaction site comprises a site on or in the substrate at which the anti-diuron antibody is combined with the hapten to allow binding of the antibody to the hapten if diuron is not present in the sample.
  • the hapten of diuron is located at the reaction site, and the hapten, anti-diuron antibody and liquid sample are combined through movement of the anti-diuron antibody and the liquid sample through the substrate to the reaction site.
  • movement of the sample through the substrate transports the anti-diuron antibody and diuron (if present) in the sample to the reaction site.
  • the device may comprise a control antibody which is capable of binding the anti-diuron antibody.
  • the reaction site comprises the control antibody.
  • the reaction site comprises the hapten of diuron at the first location (also referred to herein as the test site) and a control antibody at a control location that is separate from the first location (also referred to herein as the control site), wherein movement of the liquid sample from the sample receiving portion to the reaction site combines the anti-diuron antibody with the hapten of diuron at the first location, and the anti-diuron antibody with the control antibody at the control location.
  • movement of the liquid sample through the substrate transports the anti-diuron antibody and diuron (if present) to the reaction site where the anti-diuron antibody may bind to the hapten at the test site if it has not bound diuron, and where the control antibody binds anti-diuron antibody at the control site.
  • the anti-diuron antibody bound by the control antibody will be detectable at the control site irrespective of whether diuron is present in the sample.
  • movement of the liquid sample through the substrate is by capillary action.
  • the hapten of diuron is represented by formula I;
  • X is a protein selected from the group consisting of Bovine Serum Albumin (BSA) and Ovalbumin (OVA) ; and n is from 3 to 5.
  • BSA Bovine Serum Albumin
  • OVA Ovalbumin
  • X is OVA and n is 5; X is OVA and n is 3; X is BSA and n is 3; and X is BSA and n is 5. Typically, X is BSA and n is 5.
  • X is typically BSA and n is typically 5.
  • the inventors have surprisingly found that by using the hapten of formula I in which X is BSA and n is 5 in a lateral flow device, sensitivity of the lateral flow device is greatly increased compared to when other haptens of diuron are used.
  • the inventors have found that by using a hapten of formula I in which X is BSA and n is 5, amounts of diuron in a sample as low as 1 part per billion can be detected.
  • any of the following haptens of formula I can be used: X is BSA and n is 3; X is OVA and n is 3; X is OVA and n is 5.
  • the inventors have thus found that by varying the chemical structure of the hapten of diuron that is employed in the device, devices of different sensitivity can be prepared.
  • the sensivity of the device may also be reduced by increasing the amount of hapten of diuron at the first location .
  • the anti-diuron antibody binds diuron and the hapten of diuron.
  • the anti-diuron antibody is unable to bind the hapten of diuron, or the ability of the anti-diuron antibody to bind the hapten of diuron is reduced.
  • the anti-diuron antibody is raised against a diuron immunogen.
  • the diuron immunogen may be a compound of formula II:
  • Xi is a protein selected from the group consisting of BSA, OVA and keyhole limpet hemocyanin (KLH) ;
  • n is from 3 to 5.
  • X is BSA and n is 3; X is BSA and n is 5; X is KLH and n is 3; and X is KLH and n is 5.
  • X is KLH and n is 3.
  • the substrate may be any material that permits movement of liquid from the sample receiving portion to the reaction site.
  • the substrate is a plurality of membranes which are in contact to permit fluid movement between the membranes.
  • the sample receiving portion may be a sample receiving pad, in contact with an antibody reagent pad which is in turn in contact with a permeable membrane on which is located the reaction site.
  • the sample receiving pad, antibody reagent pad and permeable membrane are arranged to permit flow of fluid from the sample receiving pad to the permeable membrane via the antibody reagent pad.
  • the substrate may further comprise a reservoir pad which is typically in contact with the permeable membrane at a site distal to the antibody reagent pad.
  • the reservoir pad is arranged to receive the liquid sample after the hapten, antibody and liquid sample have combined at the reaction site.
  • the permeable membrane may be any membrane which permits a liquid to move from one location to another, typically by capillary action.
  • the sample receiving pad, antibody reagent pad and permeable membrane may all be a fibrous membrane made from materials such as glass fibre, cellulose, polyester, cotton, spun polyethylene,
  • the sample receiving pad is glass fibre.
  • the antibody pad is glass fibre. Glass fibre may be obtained from, for example, Gold-Bio Co., Ltd, Shanghai, China .
  • membrane is a nitrocellulose membrane.
  • the antibody may be labeled with any label which permits detection of the antibody.
  • the antibody may be labeled with horse radish peroxidase, phosphatase, a fluorescent tag, colloidal gold label.
  • the antibody is labeled with colloidal gold label.
  • colloidal gold label can be viewed directly without addition of further reagents and therefore avoids the necessity for addition of developing reagents.
  • the use of colloidal gold label in the device therefore permits rapid and convenient detection.
  • Fig. 1 illustrates a side view of the arrangement of an embodiment of the lateral flow device (11) .
  • the substrate (12) comprises a sample
  • the sample receiving pad (13) is typically composed of fibrous material such as cotton, glass fibre, cellulose,
  • the sample receiving pad (13) is in contact with the antibody reagent pad (14) .
  • the antibody reagent pad (14) may be formed from any permeable material such as, for example, cotton, glass fibre, cellulose, polyester, nitrocellulose or nylon.
  • the antibody reagent pad (14) comprises labeled anti-diuron antibody.
  • the anti-diuron antibody is an antibody raised against a diuron immunogen such as a compound of formula II described above. Typically, the anti-diuron antibody is raised against an immunogen of formula II in which Xi is KLH and n is 3.
  • the anti-diuron antibody can be labeled with any label which permits detection of the antibody in the device.
  • the label may be a particulate metal, an enzyme, a chromogenic substrate, a chromophore, or fluorescent or chemiluminescent molecules.
  • the antibody can be labeled with horse radish peroxidase (HRP) , phosphatase, or colloidal gold.
  • HRP horse radish peroxidase
  • phosphatase phosphatase
  • colloidal gold Typically, the antibody is labeled with colloidal gold.
  • the permeable membrane has a reaction site (16) located downstream of the antibody reagent pad.
  • the permeable membrane may be formed from any material that is permeable such as cotton, glass fibre, polyester,
  • the permeable membrane (15) is formed from nitrocellulose.
  • the permeable membrane is typically elongate, such as in the form of a strip.
  • a permeable reservoir pad (17) is typically in contact with the other end of the permeable membrane.
  • the reservoir pad is typically formed from absorbant material such as cotton, glass fibre, polyester, cellulose, nitrocellulose or nylon.
  • the reaction site (16) is located between the antibody reagent pad and the reservoir pad (17) and comprises a test site (18) and typically a control site (19) .
  • the test site typically comprises the hapten of diuron arranged on or in the membrane.
  • the hapten of diuron is typically arranged in a pattern or shape that is easily detectable by a user of the device.
  • the hapten of diuron may be arranged in a line or band (18) across the permeable membrane.
  • the hapten of diuron is typically immobilised on the membrane. Methods for immobilizing antigens on permeable membranes are known in the art.
  • the hapten may be immobilised on the permeable membrane by drying the hapten on the permeable membrane as described in, for example, Peng et al. (2007) Intern. J. Environ. Anal. Chem. 87:275-283. Methods for immobilization of antigens on permeable membranes are also described in, for example, US patent no. 7,736,890.
  • the control site (19) is typically located downstream (closer to the reservoir pad) of the test site and contains a control antibody which binds the anti- diuron antibody.
  • the control antibody will be an anti-rabbit antibody.
  • suitable anti-rabbit antibodies include goat anti-rabbit IgG, mouse anti-rabbit IgG, donkey anti-rabbit IgG or bovine anti-rabbit IgG.
  • Suitable anti-rabbit antibodies are available from, for example, Thermo Fisher Scientific, Inc.
  • the control antibody is typically arranged in a pattern or shape that is easily detectable by a user of the device.
  • the control antibody may be arranged in a line or band (19) across the permeable membrane.
  • the control antibody is typically immobilized on the permeable membrane. Methods for immobilizing antibodies on
  • control antibody may be immobilised on the permeable membrane by drying the control antibody on the permeable membrane as described in, for example, Peng et al . (2007) Intern. J. Environ. Anal. Chem. 87:275-283.
  • Fig. 2 is a diagram of an embodiment of the lateral flow device showing the arrangement of the sample receiving pad (13), antibody reagent pad (14), permeable membrane (15) and reservoir pad (17) in relation to the outer casing.
  • the permeable membrane (15) is arranged on a solid support member (30) which is typically formed from plastic.
  • the permeable membrane is typically secured on the support member by an adhesive.
  • the sample receiving pad (13) and antibody reagent pad (14) are in contact with one end of the permeable membrane (15)
  • the reservoir pad (17) is in contact with the other end of the permeable membrane (15) .
  • the support member (30) has projections (32) extending from its upper surface which restrict lateral movement of the substrate.
  • the device comprises a housing member (33) , formed typically from plastic, which is placed over the membranes and engages with the support member (30) to lock the housing member in place over and around the substrate.
  • the housing member includes a sample window (34) and viewing window (35) .
  • the sample window (34) aligns over the sample receiving pad (13) allowing application of a sample to the sample pad through the sample window.
  • the viewing window (35) is positioned over the reaction site (16) to permit viewing of the result after a sample has been applied.
  • a liguid sample is prepared by mixing a sample to be tested, such as a food, drink or
  • a liquid typically water or a buffer such as phosphate buffered saline (PBS), pH 7.5.
  • PBS phosphate buffered saline
  • the liquid sample is applied through the sample window (34) onto the sample receiving pad (13) .
  • the liquid sample flows through the sample receiving pad (13) into the antibody reagent pad (14) comprising anti-diuron antibody.
  • the fluid sample mixes with the anti-diuron antibody and the mixture of sample and anti-diuron antibody flows, by capillary action, into the permeable membrane (15) towards the reaction site (16) .
  • the sample and anti-diuron antibody contacts the test site (18) .
  • the anti-diuron antibody can bind to the hapten of diuron immobilised at the test site if diuron is not already bound by the antibody.
  • the diuron in the sample will be bound by the anti-diuron antibody and will therefore be prevented or competitively inhibited from binding the hapten of diuron at the test site.
  • no antibody binding will be detectable, or at least antibody binding will be reduced at the test site. If no diuron is present in the sample, the anti-diuron antibody will then be free to bind to the hapten of diuron at the test site.
  • the anti-diuron antibody can be detected bound to the hapten of diuron at the test site.
  • the sample and antibody mixture then flows by capillary action to the control site where anti-diuron antibody is bound by the control antibody.
  • anti-diuron antibody bound to the control antibody can be detected at the control site. Binding of the anti-diuron antibody by the control antibody indicates that a
  • Anti-diuron antibody bound to the hapten of diuron can be detected by detecting the antibody label.
  • gold bound to the anti-diuron antibody can be visually detected without the need for developing reagents.
  • the anti-diuron antibody has a label such as horse radish peroxidase or a fluorescent label
  • the antibody bound to the hapten can be detected using the appropriate developing reagents or viewing conditions. Developing reagents and viewing conditions for various labels are known in the art and readily available commercially from, for example, Millipore, MA, Promega Corporation or BD Biosciences.
  • Fig. 3 shows an example of results following application of a sample to the device. Binding of the antibody to the hapten can be visualised through the viewing window (35) . For example, if the hapten of diuron and the control antibody is applied as a line across the test strip, then binding of the antibody to both test and control can be visualized as two visible lines (18) and (19) across the test strip if diuron is not present in the sample. If diuron is present in the sample, then only the control line (19) will be visible, or the test line will be visibly less than the control line.
  • the haptens were attached to proteins using a N- hydroxysuccinimide reaction as described in Karu et al . (1994) J. Agric. Food Chem. 42:301-309.
  • reaction steps for preparation of the haptens are as follows : Step one: preparation of a spacer
  • Step two preparation of the hapt
  • Step three preparation of the active ester (0.17 mmol Hapten 4C/6C, 0.22 mmol NHS added in 2.2 mL dry THF, 0.22 mmol DCC)
  • Step four Preparation of protein conjugate of the haptens A) water
  • Conjugates 300 yL and sterile physiological saline (1700 pL) were mixed with 2mL of Freund' s complete (first immunization), so that lmg/rabbit was injected.
  • Boost injections were performed half dose at every two weeks intervals .
  • ND Not determined due to death ofrabbit.
  • hapten 4C-OVA and hapten 6C-OVA The two types of coating antigens performed egually well (50% inhibition at 0.48 ⁇ g/ and 15% inhibition at 0.04 ⁇ g/L and 0.05 g/L respectively (Fig. 4A) .
  • Fig. 4D shows that the mid-point of the standard curve for diuron was 0.18 ppb and it 0.03 ppb at 15% inhibition.
  • nitrocellulose membrane The test strip was arranged as set out in Figs. 1 and 2 and as described above. Goat anti-rabbit antibody was used as the control antibody. Hapten of diuron, antibody to hapten 4C-KLH and control antibody were applied to the permeable membrane as described in Peng et al . (2007) Intern. J. Environ. Anal. Chem. 87: 275-283. The preparation of the assay
  • Hapten 4C and Hapten 6C were conjugated with OVA and BSA using NHS or EDC reaction to prepare coating-antigens as described in Kramer, et al . (2004) J. Agric. Food Chem. 52: 2462-2471, M.H. Goodrow, B.D.
  • NC membranes were obtained and tested for use as a membrane in the assay: • HF090, 6 cm x 30cm (8 pm) and HFB18002 2.5 cm x lOOmtrs (5 pm) were obtained from Millipore Corporation, Bedford;
  • Millipore 180s was chosen, since it released labeled antibody slightly slower than 135s, but with greater sensitivity . iv. Sample solute
  • NC membrane HFB18002 (Millipore Corp.)
  • Control antibody goat anti-rabbit IgG
  • diuron was detected in samples containing diuron at concentrations as low as 1 part per billion .

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur un dispositif à écoulement latéral pour la détection de diuron dans un échantillon comprenant : (a) un substrat comprenant une partie de réception d'échantillon et un site de réaction, le substrat ayant une structure permettant le déplacement d'un échantillon liquide de la partie de réception d'échantillon vers le site de réaction; (b) un haptène du diuron en un premier emplacement; et (c) un anticorps dirigé contre le diuron en un second emplacement qui est séparé du premier emplacement, l'haptène et l'anticorps dirigé contre le diuron étant disposés de façon que, lorsque l'échantillon liquide est appliqué à la partie de réception d'échantillon, l'haptène, l'anticorps et l'échantillon liquide sont combinés au niveau du site de réaction par déplacement de l'échantillon liquide de la partie de réception d'échantillon vers le site de réaction. L'invention porte également sur des procédés de détection de diuron dans un échantillon liquide utilisant le dispositif à écoulement latéral, et sur une trousse comprenant le dispositif à écoulement latéral.
PCT/AU2011/001645 2010-12-20 2011-12-20 Dispositif à écoulement latéral pour la détection de diuron Ceased WO2012083356A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011349119A AU2011349119B2 (en) 2010-12-20 2011-12-20 Lateral flow device for the detection of diuron

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201010609718.2 2010-12-20
CN201010609718.2A CN102539732B (zh) 2010-12-20 2010-12-20 横向流动装置
AU2011900884 2011-03-11
AU2011900884A AU2011900884A0 (en) 2011-03-11 Lateral flow device

Publications (1)

Publication Number Publication Date
WO2012083356A1 true WO2012083356A1 (fr) 2012-06-28

Family

ID=46312894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2011/001645 Ceased WO2012083356A1 (fr) 2010-12-20 2011-12-20 Dispositif à écoulement latéral pour la détection de diuron

Country Status (2)

Country Link
AU (1) AU2011349119B2 (fr)
WO (1) WO2012083356A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089027A2 (fr) * 2005-02-18 2006-08-24 Charm Sciences, Inc. Kit d'analyse a ecoulement lateral et procede de detection d'analyte

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089027A2 (fr) * 2005-02-18 2006-08-24 Charm Sciences, Inc. Kit d'analyse a ecoulement lateral et procede de detection d'analyte

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE, N. ET AL.: "Quantification of the Urea Herbicide, Diuron, in Water by Enzyme Immunoassay", BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY, vol. 55, 1995, pages 479 - 486 *

Also Published As

Publication number Publication date
AU2011349119B2 (en) 2016-04-14
AU2011349119A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
Watanabe et al. Monoclonal-based enzyme-linked immunosorbent assay and immunochromatographic assay for enrofloxacin in biological matrices
Stevenson Immuno-affinity solid-phase extraction
Venkataramana et al. Development and validation of an immunochromatographic assay for rapid detection of fumonisin B1 from cereal samples
US8003766B2 (en) Monoclonal antibody specific to ochratoxin A
Liu et al. Highly efficient detection of salbutamol in environmental water samples by an enzyme immunoassay
Liu et al. Development of a monoclonal antibody based-ELISA for the detection of chloramphenicol in shrimp, feed and milk samples and validation by LC-MS/MS coupled with immunoaffinity clean-up
Hu et al. Detection of microcystins in environmental samples using surface plasmon resonance biosensor
Jiao et al. Binding properties of broad-specific monoclonal antibodies against three organophosphorus pesticides by a direct surface plasmon resonance immunosensor
Rivasseau et al. Potential of immunoextraction coupled to analytical and bioanalytical methods (liquid chromatography, ELISA kit and phosphatase inhibition test) for an improved environmental monitoring of cyanobacterial toxins
Liu et al. Development of a chemiluminescence enzyme-linked immunosorbent assay for the simultaneous detection of imidaclothiz and thiacloprid in agricultural samples
Kaufman et al. Immunoassay of pesticides: an update
González-Martı́nez et al. Reversible immunosensor for the automatic determination of atrazine. Selection and performance of three polyclonal antisera
Abuknesha et al. A highly sensitive and specific enzyme immunoassay for detection of β-amanitin in biological fluids
Izumi et al. Anti-bilirubin monoclonal antibody II. Enzyme-linked immunosorbent assay for bilirubin fractions by combination of two monoclonal antibodies
Wang et al. Development of a competitive indirect enzyme-linked immunosorbent assay for screening phenylethanolamine A residues in pork samples
US4454226A (en) Enzymatic immunoassay
Xu et al. Development of competitive ELISA and CLEIA for quantitative analysis of polymyxin B
Mhadhbi et al. Generation and characterization of polyclonal antibodies against microcystins—application to immunoassays and immunoaffinity sample preparation prior to analysis by liquid chromatography and UV detection
Campanella et al. Reliable new immunosensor for atrazine pesticide analysis
Du et al. Sensitive and specific detection of a new β-agonist brombuterol in tissue and feed samples by a competitive polyclonal antibody based ELISA
Wilkinson et al. Immunological analysis of mycotoxins
JP2659220B2 (ja) 除草剤の免疫学的検知方法
AU2011349119B2 (en) Lateral flow device for the detection of diuron
Liu et al. Sensitive detection of thiacloprid in environmental and food samples by enhanced chemiluminescent enzyme immunoassay
Yan et al. Development of an enzyme-linked immunosorbent assay for the simultaneous determination of parathion and imidacloprid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11850411

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2011349119

Country of ref document: AU

Date of ref document: 20111220

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11850411

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03/12/2013)